These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
455 related articles for article (PubMed ID: 25655613)
1. Treatment strategies in mantle cell lymphoma. Maddocks K; Blum KA Cancer Treat Res; 2015; 165():251-70. PubMed ID: 25655613 [TBL] [Abstract][Full Text] [Related]
2. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Vose JM Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436 [TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma. William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781 [TBL] [Abstract][Full Text] [Related]
4. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era? Chaudhary L; Kharfan-Dabaja MA; Hari P; Hamadani M Bone Marrow Transplant; 2013 Nov; 48(12):1489-96. PubMed ID: 23584438 [TBL] [Abstract][Full Text] [Related]
5. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management. Vose JM Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091 [TBL] [Abstract][Full Text] [Related]
6. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL). Dawar R; Hernandez-Ilizaliturri F Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454 [TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
8. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Vose JM Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102 [TBL] [Abstract][Full Text] [Related]
9. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice. Avivi I; Goy A Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189 [TBL] [Abstract][Full Text] [Related]
10. Unmet needs in the treatment of mantle cell lymphoma. Rosen ST; Link BK; Fowler NH Clin Adv Hematol Oncol; 2013 Nov; 11(11 Suppl 18):1-19. PubMed ID: 24893041 [TBL] [Abstract][Full Text] [Related]
11. Current regimens and novel agents for mantle cell lymphoma. Chen Y; Wang M; Romaguera J Br J Haematol; 2014 Oct; 167(1):3-18. PubMed ID: 24974852 [TBL] [Abstract][Full Text] [Related]
12. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation. Nazeef M; Kahl BS Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443 [TBL] [Abstract][Full Text] [Related]
13. [Current strategies in the treatment of advanced stage mantle cell lymphoma]. Lenz G; Dreyling M; Unterhalt M; Hiddemann W Dtsch Med Wochenschr; 2004 Nov; 129(45):2429-33. PubMed ID: 15529247 [TBL] [Abstract][Full Text] [Related]
14. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease. Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332 [TBL] [Abstract][Full Text] [Related]